Long-term acetyl-L-carnitine treatment in Alzheimer's disease - Wikidata - awgldk - TriplyDB

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

http://www.wikidata.org/entity/Q28333901

about

Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development L-carnitine for cognitive enhancement in people without cognitive impairment Acetyl-l-carnitine for dementia L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2 Localization of organic cation/carnitine transporter (OCTN2) in cells forming the blood-brain barrier.The use of medications for cognitive enhancement.Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study.Complementary and alternative medicines for Alzheimer's disease.Acetyl-L-carnitine ameliorates mitochondrial dysfunction following contusion spinal cord injury.Ongoing trials in Alzheimer's disease.Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression.Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites.Antioxidants as treatment for neurodegenerative disorders.Oxidative damage and cognitive dysfunction: antioxidant treatments to promote healthy brain aging Effectiveness of nutritional supplements on cognitive functioning in elderly persons: a systematic review.Acetyl-L-carnitine treatment following spinal cord injury improves mitochondrial function correlated with remarkable tissue sparing and functional recovery.Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia.Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease.Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia.Different methods to analyze clinical experiments with multiple endpoints: a comparison of real data.Magnetic resonance spectroscopic changes in Alzheimer's disease.Vitamins and nutrients as primary treatments in experimental brain injury: Clinical implications for nutraceutical therapies.Natural antioxidants in Alzheimer's disease.Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity.High-throughput chinmedomics-based prediction of effective components and targets from herbal medicine AS1350.Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond.Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders.L-carnitine for cognitive enhancement in people without cognitive impairment.Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere.Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine.Chronic liver disease questionnaire would be a primary screening tool of neuropsychiatric test detecting minimal hepatic encephalopathy of cirrhotic patients.Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia Acetyl-L-carnitine reduces the infarct size and striatal glutamate outflow following focal cerebral ischemia in rats.ST1859 reduces prion infectivity and increase survival in experimental scrapie.Transport of L-carnitine in isolated cerebral cortex neurons.Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease.Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.Scientific Opinion on the substantiation of health claims related to acetyl-L-carnitine and contribution to normal cognitive function (ID 1432) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps.

P2860

Q22241837-E5ED91B9-4C8F-4F04-AF09-E52884167C90 Q24188229-78AAECE0-2E1D-4093-9054-587397907B40 Q24248643-00347A1E-D6F5-442D-B334-DDAEA00D0E2E Q24298663-BADBDD94-F78E-473B-B051-394E9C99E61B Q30837035-AA0D5122-3FF7-4D00-89F9-5C6F02011C3B Q32122238-97FC048E-91D8-43F6-AF6B-ECF4270FD2A1 Q33326646-E28A7220-B235-479A-935E-547FE02E10C4 Q33609573-F76A8385-1C81-4F1B-897B-CC02D1E85978 Q33965418-F245A73C-7B98-4660-924C-C5175E3A859E Q34074827-B4DE2298-5B86-42D3-AEFF-9FB9FE4EF22A Q34111025-4E40BD54-205F-43FF-956A-7A5DFF2B4DC3 Q34614478-148CC63C-2237-4094-9370-DE4D2FEBB08F Q34974866-0495CA37-716D-4638-BFE4-5C1600CCCAD8 Q35359185-3E54F46E-83CA-4F70-AF35-84B420303FEF Q35940587-BA097B64-18BD-44D0-AE38-8375769693CC Q35980880-8DE000F2-DD41-43B1-9E35-2883E3CE20CD Q36022519-E9838A20-51AC-4436-85DE-D7D218110132 Q36212135-845213B7-F5C6-401A-9487-39647255A69D Q36568506-791BE27B-4D93-4307-9D15-238A8AF75018 Q36810457-FF64B527-8FFE-4536-8CA1-A190B89334D2 Q36885911-884917FB-80EE-4190-A4D3-DD4ECBF5E0DA Q36909351-76A2FF2C-F4EB-47DF-A1B4-D52C6701FC08 Q37016092-A4142594-734E-4E6B-8318-8AC76B2BF181 Q37217435-A93540A2-4D12-4482-93FF-EB5C31D99F95 Q37464707-DCCC3E2D-ED98-44EF-831D-4B6B9D146D22 Q38130554-5F2523AE-AEEC-4969-9CFD-09946F7797FE Q38229311-DC940667-4A91-492F-A29F-664103F7EA0E Q38871856-29EB2094-39F2-4177-B2F2-D4CED4A8344C Q39101800-B07CB7A7-504F-4939-A9F2-B8A78EC6F379 Q40779663-EE8EEBFA-BDDA-43D0-B363-4AAE2900A342 Q40865200-26EDF693-9259-472A-9721-824B0CC8D6AF Q41076368-9AC2A1B3-81C4-4458-9066-9AB66F841A2D Q42646705-09038D1F-569F-4790-8A71-9CCAFC332734 Q42969544-9E8DE518-24CD-45D6-B69B-2C54D080F74E Q43291009-5415F063-5717-4187-98BE-A54D155AC886 Q43558914-4B3717F8-3E01-4A3B-9309-FC934A75610D Q43709002-2A4125D0-D671-49DE-84B3-D642AE29BD04 Q46689540-D6005A4C-9E04-41BA-95BD-877405350603 Q47150105-23E723E0-B673-4979-9737-97E478AC288C Q47398802-510BDCC4-CC4A-4AD1-AAF1-FC755F730A82

P2860

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

http://www.wikidata.org/entity/Q28333901

description

1991 nî lūn-bûn

@nan

1991 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@ast

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@en

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@nl

type

label

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@ast

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@en

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@nl

prefLabel

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@ast

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@en

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@nl

P1433

Q28333901-16E1EA98-A10E-4BBD-9980-15611D33C01E

P1476

Q28333901-FB990FC7-C0DC-4EE9-99D9-57A51750E688

P2093

Q28333901-197BA828-2726-4A90-B12F-600D0A2D32A6

Q28333901-1E929E31-6FCF-4683-BBC5-65F7E17059E1

Q28333901-28523CC7-028F-4596-ABAD-B1943679A627

Q28333901-40184B3A-0E56-46E8-BC18-B4108D9D0BAD

Q28333901-4A2AB544-E509-45F8-BFFA-2A977FB20888

Q28333901-7DA5187F-8F6D-4DAF-8809-57E0F84B9B98

Q28333901-A1911F2D-4DBF-459E-AF69-328745344827

Q28333901-A66AB4F4-E297-4439-82F9-4C08A0E220E0

Q28333901-ADBDD99D-8260-4AD3-85FC-C46C41EC1BFD

Q28333901-CAC809A3-E371-43D8-866B-59D58520A69A

P304

Q28333901-4BF5FE2C-59FB-46A3-A89C-5DD0695FF6E2

P31

Q28333901-F4A29683-D155-4736-A7DD-1C01C34F5554

P3181

Q28333901-89CAC511-AB4E-457F-BB89-BAE79C7FE460

P356

Q28333901-0088E77B-CE7E-40A3-9355-7D1DE53795DA

P407

Q28333901-1456CF22-C656-4B17-A17C-4FDA1793754F

P433

Q28333901-16390500-1631-488E-A2B4-B8C4B9518692

P478

Q28333901-AF26817E-9E11-4E32-BFA7-C216115358A0

P577

Q28333901-E0CA183A-D1A6-4920-B65E-D1FE8323DB21

P698

Q28333901-642929CE-58D3-4A3F-B17F-DA52352BBC05

P921

Q28333901-898EA402-DB07-4CFA-B46D-05822FB531AF

P3181

P356

P1433

P1476

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

@en

P2093

A Spagnoli

http://www.w3.org/2001/XMLSchema#string

G Cizza

http://www.w3.org/2001/XMLSchema#string

G Forloni

http://www.w3.org/2001/XMLSchema#string

G Menasce

http://www.w3.org/2001/XMLSchema#string

L Bandera

http://www.w3.org/2001/XMLSchema#string

L Frattura

http://www.w3.org/2001/XMLSchema#string

M Comelli

http://www.w3.org/2001/XMLSchema#string

M Tettamanti

http://www.w3.org/2001/XMLSchema#string

P Tiraboschi

http://www.w3.org/2001/XMLSchema#string

U Lucca

http://www.w3.org/2001/XMLSchema#string

P304

1726-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1501225

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/WNL.41.11.1726

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

1991-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1944900

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease